BS, MS, PhD
FATS - Fellow Academy of Toxicological Sciences, DABT - Diplomate American Board of Toxicology
Dr. Bill Brock received his Ph.D. in toxicology from the University of Kentucky (1983), and did a post-doctoral fellowship at UK. Dr. Brock is a Diplomate of ABT, a Fellow of ATS, and has served as a Board member and President for both ABT and ATS. Dr. Brock has served in various leadership capacities or as a member of various professional organizations and committees for the ACT, SOT and others. Dr. Brock is an Associate Editor for the International Journal of Toxicology, and a reviewer for Food and Chemical Toxicology, Toxicological Sciences, Toxicology and Industrial Health, Current Eye Research and other leading toxicology journals.
Art Materials, Biologics/Biotherapeutics/Biotechnology, Carcinogenicity, Clinical Trials (Phases I- II- III- IV), Consumer Products, Dermal Toxicology, Drug/Pharmaceutical Development, Drugs of Abuse and Alcohol, Expert Witnessing, Food and Food Additives, GLP Study Auditing, Hazard Communication, Hepatic Toxicology, In Vitro Toxicology, Industrial and Occupational Toxicology, Inhalation and Respiratory Toxicology, Litigation Support, Neurotoxicology, Ocular Toxicology, Over-The Counter Products, Pharmacokinetics/Toxicokinetics, Product Safety Assessment, Regulatory Toxicology, Risk Assessment, Safety Pharmacology, Training and Training Courses
Dr. Brock’s technical expertise includes pharmacology and toxicology research and testing advice for early- through late-stage pharmaceutical development for worldwide regulatory submissions. Preparation of regulatory dossier (IND/NDA/BLA) and responses to regulatory inquiries. Provides scientific and regulatory consulting advice and safety and risk assessments to clients in the chemical, medical device, food and consumer product industries. Has expertise for degradant/impurity and excipient qualifications including genotoxic impurity assessments. Expertise in general toxicology, dermal and ocular toxicology, animal models, experimental design and testing with numerous CROs, litigation support and expert witness testimony and toxicology report preparation and review. Please see http://www.brocksc.com for full details.
From his post-doctoral fellowship, he joined DuPont’s Haskell Laboratory and spent 17 years in various research, testing and management roles. Subsequently, Bill joined Unilever, a world-wide consumer product company, and then the international consulting firm Environ. In 2010, he joined Otsuka Pharmaceuticals and became the Director of Toxicology where he was responsible for all aspects of regulatory toxicology for developmental candidates for a wide variety of therapeutic areas including oncology, CNS, cardiorenal, vaccines, dermatology and ophthalmology. He was primarily responsible for nonclinical issues for the US, Canada and Europe but advised on nonclinical issues for other regions. He served as a nonclinical reviewer for a FDA Advisory Committee (CARDAC) and has managed a basic research program for a cardiorenal therapeutic.
19909 Hamil CIr